Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BIIB

Biogen Inc

Oct 04 • 04:00PM ET

185.68

Dollar change +0.90
Percentage change 0.49	%

Healthcare • Drug Manufacturers - General • USA • NASD

Held by: VTI VOO VO QQQ SPY IVV VTV VOE XLV IBB

Scroll to Statements

Index	NDX, S&P 500	P/E	23.39	EPS (ttm)	7.94	Insider Own	0.81%	Shs Outstand	144.90M	Perf Week	-4.62%
Market Cap	27.05B	Forward P/E	10.82	EPS next Y	17.16	Insider Trans	-0.04%	Shs Float	144.48M	Perf Month	-7.99%
Income	1.16B	PEG	3.90	EPS next Q	3.78	Inst Own	89.07%	Short Float	2.54%	Perf Quarter	-18.59%
Sales	9.29B	P/S	2.91	EPS this Y	9.34%	Inst Trans	-0.55%	Short Ratio	3.50	Perf Half Y	-8.92%
Book/sh	109.05	P/B	1.70	EPS next Y	6.63%	ROA	4.46%	Short Interest	3.67M	Perf Year	-27.80%
Cash/sh	13.11	P/C	14.17	EPS next 5Y	6.00%	ROE	7.63%	52W Range	183.56 - 269.43	Perf YTD	-28.25%
Dividend Est.	-	P/FCF	17.28	EPS past 5Y	-18.05%	ROI	5.14%	52W High	-31.08%	Beta	-0.07
Dividend TTM	-	Quick Ratio	1.48	Sales past 5Y	-4.53%	Gross Margin	68.37%	52W Low	1.15%	ATR (14)	4.42
Dividend Ex-Date	-	Current Ratio	2.29	EPS Y/Y TTM	-56.80%	Oper. Margin	19.52%	RSI (14)	32.05	Volatility	1.95% 2.12%
Employees	7570	Debt/Eq	0.43	Sales Y/Y TTM	-1.91%	Profit Margin	12.47%	Recom	1.69	Target Price	268.41
Option/Short	Yes / Yes	LT Debt/Eq	0.42	EPS Q/Q	-1.62%	Payout	0.00%	Rel Volume	1.08	Prev Close	184.78
Sales Surprise	3.03%	EPS Surprise	29.79%	Sales Q/Q	0.09%	Earnings	Aug 01 BMO	Avg Volume	1.05M	Price	185.68
SMA20	-5.14%	SMA50	-7.92%	SMA200	-16.05%	Trades		Volume	1,136,999	Change	0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327
Jul-24-23	Reiterated	UBS	Buy	$346 → $335
May-01-23	Upgrade	Guggenheim	Neutral → Buy	$270 → $350
Apr-17-23	Upgrade	Piper Sandler	Neutral → Overweight	$280 → $346
Oct-26-22	Upgrade	Goldman	Neutral → Buy	$220 → $370
Oct-13-22	Upgrade	Stifel	Hold → Buy	$223 → $299
Oct-07-22	Upgrade	Argus	Hold → Buy	$300
Sep-28-22	Upgrade	Robert W. Baird	Neutral → Outperform	$224 → $340
Sep-28-22	Upgrade	Mizuho	Neutral → Buy	$207 → $270
Sep-28-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$217 → $360
Apr-18-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$235 → $265
Mar-08-22	Downgrade	Stifel	Buy → Hold	$304 → $223
Mar-03-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$227 → $248
Feb-04-22	Reiterated	Wolfe Research	Peer Perform	$244 → $217

Show Previous Ratings

Oct-03-24 09:25AM	UBS sees more downside and than upside in Biogen stock (Investing.com)
Oct-02-24 01:33PM	Is Eli Lilly Stock A Buy After Snagging Approval For A New Eczema Drug? (Investor's Business Daily)
06:52AM	Biogen scrapped stroke drug helps patients walk independently in Phase III trial (Clinical Trials Arena)
Oct-01-24 08:46PM	Biogen Inc. (BIIB): Among the Best Bargain Stocks to Buy In October (Insider Monkey)
Sep-26-24 10:37AM	Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate (Benzinga)
11:05AM	Loading…
Sep-24-24 11:05AM	Biogen stock opened higher on positive lupus readout (Investing.com)
08:19AM	Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial (Benzinga)
06:33AM	UCB and Biogen lupus drug succeeds in Phase III, but data yet to be released (Clinical Trials Arena)
01:00AM	UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024 (GlobeNewswire)
Sep-23-24 09:00PM	Biogen, UCB get the lupus data theyve waited two decades for (BioPharma Dive)
Sep-20-24 08:00AM	Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ (GlobeNewswire)
Sep-16-24 09:40AM	Here's Why Biogen Inc. (BIIB) is a Strong Value Stock (Zacks)
01:52AM	Hope remains that Roches prasinezumab can overcome recent string of failures in Parkinsons disease (Clinical Trials Arena)
Sep-13-24 06:55AM	Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial (BioPharma Dive)
Sep-12-24 03:32PM	Healthcare Stocks Have Popped. Consider These 2 That Havent. (Barrons.com)
07:30AM	Loading…
07:30AM	Biogen Board Appoints Two New Independent Directors (GlobeNewswire)
Sep-06-24 12:53PM	Biogens higher Spinraza dose shows better efficacy in Phase II/III trial (Pharmaceutical Technology)
07:00AM	Pandemic Darling Moderna Needs a Reality Check (The Wall Street Journal)
Sep-05-24 12:00PM	Long-Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encouraged to Contact Johnson Fistel, LLP for Their Options (GlobeNewswire)
Sep-04-24 10:43AM	Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder (Benzinga)
08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
07:30AM	Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA (GlobeNewswire)
Aug-26-24 10:15AM	Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encouraged to Contact Johnson Fistel, LLP for Their Options (GlobeNewswire)
Aug-22-24 01:45PM	Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement (Benzinga)
12:33PM	Eisais Leqembi deemed too costly for NHS (Pharmaceutical Technology)
09:40AM	Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term (Zacks)
07:38AM	UK approves Leqembi, but reimbursement may not follow (BioPharma Dive)
05:10AM	Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain (PR Newswire)
Aug-20-24 09:00AM	Do Options Traders Know Something About Biogen (BIIB) Stock We Don't? (Zacks)
Aug-15-24 12:45PM	Is Eli Lilly Stock A Buy Or A Sell After Mounjaro And Zepbound Crush Expectations? (Investor's Business Daily)
09:05AM	Loading…
Aug-11-24 09:05AM	A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys. (Motley Fool)
Aug-09-24 09:00AM	As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032 (PR Newswire)
Aug-02-24 09:40AM	Here's Why Biogen Inc. (BIIB) is a Strong Value Stock (Zacks)
Aug-01-24 04:00PM	Biogen Stock Slips As Alzheimer's Drug Looks Abroad For Quarterly Beat (Investor's Business Daily)
03:26PM	Analyst Report: Biogen Inc. (Morningstar Research)
01:32PM	Biogen (BIIB) Q2 2024 Earnings Call Transcript (Motley Fool)
12:25PM	Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised (Zacks)
11:49AM	Midday movers: Meta Platforms, Lilly rise; Arm, Moderna fall (Investing.com)
11:23AM	Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple Sclerosis Med Sales (Benzinga)
09:37AM	Biogen Lifts Earnings Guidance After Revenue Beats Forecasts (The Wall Street Journal)
09:30AM	Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:05AM	Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates (Zacks)
07:28AM	Biogen Earnings Flat; Biotech Giant Raises Guidance (Investor's Business Daily)
06:50AM	Biogen lifts profit forecast, signals progress in turnaround effort (Reuters)
Jul-31-24 02:33PM	Is Eli Lilly Stock A Sell On A Second Stumble In Obesity Treatment? (Investor's Business Daily)
10:33AM	Biogen, Beckman Coulter and Fujirebio partner to develop Alzheimers Tau blood test (Medical Device Network)
09:00AM	Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx System for Administration of nusinersen (PR Newswire)
07:33AM	Vertexs pain drug gets speedy FDA review; Keytruda hits a sales milestone (BioPharma Dive)
Jul-30-24 05:15PM	New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC) 2024 (GlobeNewswire)
09:15AM	Countdown to Biogen (BIIB) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
07:30AM	Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease (GlobeNewswire)
Jul-29-24 01:13PM	EU CHMP snubs Biogen and Eisais Alzheimers therapy Leqembi (Pharmaceutical Technology)
11:53AM	Alzheimers Disease: Some trials to watch over the next year (Clinical Trials Arena)
10:33AM	What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback? (Zacks)
05:30AM	Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy? (Motley Fool)
Jul-28-24 09:48PM	Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug (Reuters)
08:43PM	Eisai Shares Sink on Surprise EU Rejection of Alzheimers Drug (Bloomberg)
Jul-26-24 05:12PM	S&P 500 Gains and Losses Today: 3M Stock Skyrockets After Beat-and-Raise Report (Investopedia) -7.15%
04:15PM	Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug (Investor's Business Daily)
01:14PM	Top Stock Movers Now: 3M, Charter Communications, Dexcom, and More (Investopedia)
10:48AM	EU Rejection of Alzheimers Drug Is Another Disappointment for Biogen (Barrons.com)
10:21AM	Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events (Benzinga)
09:48AM	European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval (Associated Press Finance)
07:20AM	Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union (GlobeNewswire)
Jul-25-24 10:02AM	Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for (Zacks)
04:52AM	Sage and Biogens SAGE-324 shows no benefit in essential tremor trial (Clinical Trials Arena)
Jul-24-24 04:07PM	Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails (Investor's Business Daily)
10:34AM	Sage Therapeutics Stock Slides as Pipeline Thins (Barrons.com)
09:37AM	Is Biogen (BIIB) an Underappreciated Stock? (Insider Monkey)
08:10AM	Biogen, Sage tremor drug fails key trial (BioPharma Dive)
06:30AM	Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor (Business Wire)
Jul-23-24 03:52AM	Nanotechnology in medicine: Who are the leading public companies? (Medical Device Network)
Jul-22-24 04:27PM	Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong (Investor's Business Daily)
08:14AM	Ionis plots next steps for Angelman drug Biogen passed on (BioPharma Dive)
01:12AM	Sage Therapeutics/Biogens episodic therapy zuranolone could change MDD treatment (Clinical Trials Arena)
Jul-17-24 09:50AM	Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term (Zacks)
Jul-16-24 04:02PM	Three Surprising Names That Could Be On Biogen's Buyout Shortlist (Investor's Business Daily)
12:45PM	Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights BIIB (GlobeNewswire)
11:55AM	Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense (Investor's Business Daily)
05:10AM	Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing (GlobeNewswire)
04:00AM	Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB (PR Newswire)
Jul-12-24 08:00AM	Eli Lilly Overcomes Biden-Tied Stumble To Rise Again Is Lilly Stock Now A Buy? (Investor's Business Daily)
Jul-10-24 03:25PM	ADM Hires 3M CFO Amid Government Investigation (Investopedia)
01:08PM	Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights BIIB (GlobeNewswire)
Jul-09-24 07:51PM	Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB (PR Newswire)
Jul-05-24 06:20AM	3 Highly Rated Biotech Stocks for Your July Buy List (InvestorPlace)
Jul-03-24 12:37PM	Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More (Investopedia)
11:14AM	Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence (Pharmaceutical Technology)
11:14AM	FDA Approves Eli Lilly's Alzheimer's Drug Kisunla (Investopedia)
08:00AM	Biden Just Knocked Eli Lilly Stock Off Its Pedestal Is It A Buy Or A Sell? (Investor's Business Daily)
07:55AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Jul-02-24 04:13PM	Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug (Investor's Business Daily)
02:16PM	Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai (Investor's Business Daily)
12:45PM	Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth (Insider Monkey)
09:16AM	Biogen Completes Acquisition of Human Immunology Biosciences (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-29-24 08:45PM	C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now? (Insider Monkey)
Jun-28-24 06:13AM	Eisai and Biogen launch LEQEMBI for Alzheimers in China (Pharmaceutical Technology)
Jun-27-24 09:02PM	Eisai and Biogen launch Alzheimer's drug Leqembi in China (Reuters)
07:39PM	LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China (GlobeNewswire)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Singhal Priya	Head of Development	Aug 30 '24	Option Exercise	0.00	1,668	0	6,554	Sep 05 06:00 AM
Singhal Priya	Head of Development	Sep 03 '24	Sale	204.22	431	88,019	5,316	Sep 05 06:00 AM
Singhal Priya	Officer	Sep 03 '24	Proposed Sale	204.22	431	88,019		Sep 03 01:00 PM
Keeney Adam	Head of Corporate Development	May 01 '24	Option Exercise	0.00	938	0	938	May 03 08:00 PM
Singhal Priya	Head of Development	Apr 02 '24	Sale	213.09	93	19,817	4,886	Apr 03 08:24 PM
Murphy Nicole	Head of Pharm Ops and Tech	Apr 01 '24	Option Exercise	0.00	240	0	9,751	Apr 03 08:11 PM
Singhal Priya	Head of Development	Feb 22 '24	Sale	221.23	262	57,962	4,886	Feb 26 07:54 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 16 '24	Option Exercise	0.00	5,037	0	52,506	Feb 21 09:39 PM
Gregory Ginger	EVP, Human Resources	Feb 16 '24	Option Exercise	0.00	4,704	0	14,341	Feb 21 09:36 PM
Izzar Rachid	Head of Global Product Strat.	Feb 16 '24	Option Exercise	0.00	2,017	0	10,014	Feb 21 09:33 PM
Kramer Robin	Chief Accounting Officer	Feb 16 '24	Option Exercise	0.00	1,345	0	6,354	Feb 21 09:31 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 16 '24	Option Exercise	0.00	6,720	0	20,692	Feb 21 09:29 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 16 '24	Option Exercise	0.00	1,260	0	9,624	Feb 21 09:28 PM
Singhal Priya	Head of Development	Feb 16 '24	Option Exercise	0.00	1,208	0	5,429	Feb 21 09:27 PM
Singhal Priya	Head of Development	Feb 16 '24	Sale	221.49	108	23,921	5,148	Feb 21 09:27 PM
Rowinsky Eric K	Director	Feb 15 '24	Buy	222.54	455	101,256	20,629	Feb 20 09:13 PM
Gregory Ginger	EVP, Human Resources	Feb 09 '24	Option Exercise	0.00	2,158	0	11,778	Feb 13 06:14 PM
Singhal Priya	Head of Development	Feb 09 '24	Option Exercise	0.00	1,212	0	5,309	Feb 13 06:06 PM
Singhal Priya	Head of Development	Feb 12 '24	Sale	239.45	419	100,330	4,516	Feb 13 06:06 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 09 '24	Option Exercise	0.00	2,272	0	9,529	Feb 13 06:04 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 09 '24	Option Exercise	0.00	3,257	0	17,555	Feb 13 06:03 PM
Kramer Robin	Chief Accounting Officer	Feb 09 '24	Option Exercise	0.00	833	0	5,523	Feb 13 06:01 PM
Izzar Rachid	Head of Global Product Strat.	Feb 09 '24	Option Exercise	0.00	1,515	0	9,081	Feb 13 06:00 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 09 '24	Option Exercise	0.00	2,575	0	50,021	Feb 13 05:56 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 08 '24	Option Exercise	0.00	2,190	0	48,101	Feb 09 08:16 PM
Gregory Ginger	EVP, Human Resources	Feb 08 '24	Option Exercise	0.00	1,635	0	10,118	Feb 09 08:14 PM
Izzar Rachid	Head of Global Product Strat.	Feb 08 '24	Option Exercise	0.00	2,043	0	8,187	Feb 09 08:11 PM
Kramer Robin	Chief Accounting Officer	Feb 08 '24	Option Exercise	0.00	788	0	4,943	Feb 09 08:06 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 08 '24	Option Exercise	0.00	2,335	0	15,063	Feb 09 08:03 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 08 '24	Option Exercise	0.00	2,101	0	7,895	Feb 09 08:01 PM
Singhal Priya	Head of Development	Feb 01 '24	Option Exercise	0.00	1,828	0	5,292	Feb 05 06:38 PM
Singhal Priya	Head of Development	Feb 02 '24	Sale	245.93	634	155,920	4,097	Feb 05 06:38 PM
Singhal Priya	Head of Development	Dec 08 '23	Option Exercise	0.00	426	0	3,780	Dec 12 05:06 PM
Singhal Priya	Head of Development	Dec 11 '23	Sale	248.00	110	27,280	3,464	Dec 12 05:06 PM
Kramer Robin	Chief Accounting Officer	Dec 08 '23	Option Exercise	0.00	351	0	4,325	Dec 12 05:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIIB

Biogen Inc

Upgrade your FINVIZ experience